1947

Dr. Alfredo Pavlovsky, a doctor in Buenos Aires, Argentina, distinguishes two types of hemophilia in his lab – A and B.

CSL Behring Image courtesy of CSL Behring
1952

Stephen Christmas is diagnosed with hemophilia B, which doctors colloquially refer to as Christmas Disease. Fresh frozen plasma is the only treatment option available, and the average life expectancy is less than 20 years old.

CSL Behring Image courtesy of CSL Behring

Stephen Christmas is diagnosed with hemophilia B, which doctors colloquially refer to as Christmas Disease. Fresh frozen plasma is the only treatment option available, and the average life expectancy is less than 20 years old.

Patient

Dan

Watch video of Dan’s story.
Rankin portrait of hemophilia patient, Dan

Dan has experienced the full treatment spectrum for hemophilia, from lyophilized plasma to factor. Now with a young grandson who also has hemophilia, he’s amazed by how far we’ve come and is excited for where the science is headed with gene therapy.

Dan's story
Watch video of Dan’s story.
Gary Bottoms Image courtesy of Gary Bottoms
1970s

Factor concentrates in powdered form become available, allowing for home infusions and significant reduction in treatment time.


Researchers pioneer genetic engineering, creating the potential to treat genetic conditions by modifying a person’s genes.

Gary Bottoms Image courtesy of Gary Bottoms

Factor concentrates in powdered form become available, allowing for home infusions and significant reduction in treatment time.


Researchers pioneer genetic engineering, creating the potential to treat genetic conditions by modifying a person’s genes.

Patient

Christopher

Watch video of Christopher’s story.
Rankin portrait of hemophilia patient, Christopher

Christopher was told he wouldn’t live past age 5 — but after years of health crises, he is hopeful for his future and that of his children due to the advancement of hemophilia treatments.

Christopher's Story
Watch video of Christopher’s story.
Healthcare Provider

Sue

Watch video of Sue's Story
Rankin portrait of hemophilia nurse coordinator, Sue

Sue, a now-retired nurse coordinator, spent the last three decades on the front lines caring for people with hemophilia.

Sue's story
Watch video of Sue's Story
Sue Geraghty Image courtesy of Sue Geraghty
1980s

Scientists successfully clone the Factor VIII and IX genes, paving the way for breakthrough synthetic factor therapies (not derived from human plasma) using recombinant technologies.


It is discovered that much of the human-derived clotting factor had come from blood donations contaminated with blood-borne diseases, such as HIV and hepatitis viruses.

Sue Geraghty Image courtesy of Sue Geraghty

Scientists successfully clone the Factor VIII and IX genes, paving the way for breakthrough synthetic factor therapies (not derived from human plasma) using recombinant technologies.


It is discovered that much of the human-derived clotting factor had come from blood donations contaminated with blood-borne diseases, such as HIV and hepatitis viruses.

Scientist

Ying Poi

Watch video of Ying Poi’s story.
Rankin portrait of hemophilia gene therapy scientist, Ying Poi

As a scientist working in gene therapy, Ying Poi has seen the many advancements of hemophilia treatments firsthand.

Ying Poi's story
Watch video of Ying Poi’s story.
Thomas Wilkes Image courtesy of Thomas Wilkes
1990s

The first recombinant FIX products are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat hemophilia B, leading the way for prophylactic treatment, which dramatically improve patients’ lives.


Hemophilia patient life expectancy improves to 67 years old.

Thomas Wilkes Image courtesy of Thomas Wilkes

The first recombinant FIX products are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat hemophilia B, leading the way for prophylactic treatment, which dramatically improve patients’ lives.


Hemophilia patient life expectancy improves to 67 years old.

Patient

Adam

Watch video of Adam’s story.
Rankin portrait of hemophilia patient, Adam

A child of the 90s, Adam felt comfortable engaging in most activities with family and friends thanks to the availability of prophylactic hemophilia treatments.

Adam's Story
Watch video of Adam’s story.
Healthcare Provider

Dr. Klamroth

Watch video of Dr. Klamroth’s story.
Watch video of Dr. Klamroth’s story.

A leader in the hemophilia medical community, Dr. Klamroth has witnessed several major treatment advancements over the past 25 years and looks forward to what the next 25 years will bring.

Dr. Klamroth’s Story
Watch video of Dr. Klamroth’s story.
Evidence grows for the potential
2000s

Evidence grows for the potential of adeno-associated virus (AAV) vectors to deliver safe, effective, and lasting genes that produce blood-clotting factor into the body. 

Evidence grows for the potential

Evidence grows for the potential of adeno-associated virus (AAV) vectors to deliver safe, effective, and lasting genes that produce blood-clotting factor into the body. 

Patient

Jeron

Watch video of Jeron’s story.
Rankin portrait of hemophilia patient, Jeron

Though held back from playing sports as a child, Jeron has channeled his energy into being an advocate in the hemophilia community, traveling the world and inspiring others with the condition.

Jeron's Story
Watch video of Jeron’s story.
Jennifer Mermilliod Image courtesy of Jennifer Mermilliod
2010s

Long-acting recombinant factor therapies are available offering the hemophilia community additional treatment options.


Late-stage trials for AAV-based gene therapy in hemophilia begin.

Jennifer Mermilliod Image courtesy of Jennifer Mermilliod

Long-acting recombinant factor therapies are available offering the hemophilia community additional treatment options.


Late-stage trials for AAV-based gene therapy in hemophilia begin.

Patient

Nathan

Watch video of Nathan’s story.
Watch video of Nathan’s story.

Nathan credits his happy and full childhood to his mother and his prophy regimen. Now a college student, Nathan’s journey with hemophilia has inspired him to pursue a medical degree.

Nathan’s Story
Watch video of Nathan’s story.
Caregiver

Jennifer

Watch video of Jennifer’s story.
Watch video of Jennifer’s story.

Having a child with hemophilia added another layer of worry to being a mother, but Jennifer raised her son with resilience, strength, and a dash of gratitude.

Jennifer’s Story
Watch video of Jennifer’s story.
Patient/Caregiver

Stormy

Watch video of Stormy’s story.
Rankin portrait of hemophilia patient and caregiver, Stormy

As a woman with hemophilia and a caregiver to a son with hemophilia, Stormy has made it her mission to educate others, advocating for men and women alike in the hemophilia community.

Stormy's story
Watch video of Stormy’s story.
Mike Hargett Image courtesy of Mike Hargett
2020s

Gene therapy trials in hemophilia continue and show promise in potentially decreasing annualized bleeding rates and use of replacement therapy.


The U.S. Food and Drug Administration (FDA) approves gene therapies for the treatment of hemophilia.

Mike Hargett Image courtesy of Mike Hargett

Gene therapy trials in hemophilia continue and show promise in potentially decreasing annualized bleeding rates and use of replacement therapy.


The U.S. Food and Drug Administration (FDA) approves gene therapies for the treatment of hemophilia.

Patient

Wayne

Watch video of Wayne’s story.
Rankin portrait of hemophilia patient, Wayne

As an advocate for hemophilia for over 40 years, Wayne has experienced the monumental advancements in hemophilia treatments and has committed his life to ensuring a better world for today’s hemophilia community.

Wayne's story
Watch video of Wayne’s story.